Evidence map›Paper›PMID 37314336›Full record

ArticleAntimicrobial agents and chemotherapy2023

No Association between the Plasmodium vivax

Angela Rumaseb, Roberto R Moraes Barros, Juliana M Sá, Jonathan J Juliano, Timothy William, Kamil A Braima, Bridget E Barber, Nicholas M Anstey, Ric N Price, Matthew J Grigg and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. AreBiomedicines · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

Angela RumasebGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Roberto R Moraes BarrosDepartment of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
Juliana M SáLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jonathan J JulianoDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Timothy WilliamClinical Research Centre, Queen Elizabeth Hospital, Sabah, Malaysia.
Kamil A BraimaGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Bridget E BarberGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Nicholas M AnsteyGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Ric N PriceGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Matthew J GriggGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Jutta Marfurt *Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Sarah Auburn *Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.ORCID 0000-0002-4638-536X
Charles Darwin University · AUMahidol University · THFlinders University · AUNational Institutes of Health · USQIMR Berghofer Medical Research Institute · AUQueen Elizabeth Hospital · MYUniversidade Federal de São Paulo · BRUniversity of North Carolina at Chapel Hill · US

Funding

Malaria Drug Resistance and Disease VirulenceZIAAI000483 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WELLEMS, THOMAS E · 2009 to 2025
$24.5M
6 · The paper itself

Abstract

Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ), raises concerns for the elimination of Plasmodium vivax. The absence of an effective molecular marker of CQ resistance in P. vivax greatly constrains surveillance of this emerging threat. A recent genetic cross between CQ sensitive (CQS) and CQ resistant (CQR) NIH-1993 strains of P. vivax linked a moderate CQR phenotype with two candidate markers in P. vivax CQ resistance transporter gene (

Indexed as

AntimalarialsMalaria, VivaxAllelesChloroquineDrug ResistanceHumansMalaysiaPlasmodium vivaxProtozoan ProteinsAntimalarialsChloroquineProtozoan Proteinsantimalarialchloroquinedrug resistancemalariaMalaysiamolecular markerPlasmodium vivaxpvcrt-o

Identifiers

PMID37314336
PMCPMC10353443
OpenAlexW4380577256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.